Please assess the completion status of the following clinical trial:

Trial Title: Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the ISL unit at Melrose Institute~* Diagnosed with an eating disorder (Anorexia Nervosa, Bulimia Nervosa or Eating Disorder Not Otherwise Specified)~  1. For ED-DMT1 group: Diagnosis of an eating disorder AND diagnosis of type 1 diabetes.~ 2. For ED/only group: Diagnosis of an eating disorder AND no history/diagnosis of type 1 or type 2 diabetes.~* Female.~* At least 14 years of age.~* Able to provide informed consent.~  1. If the potential participant's age is at least 18 years she must be able to provide informed consent.~ 2. If the potential participant is less than 18 years she must have a parent or guardian able and willing to provide written informed consent on the participant's behalf. In addition, the participant must be willing to sign a consent on her own behalf.~* Participants must be able and willing to utilize the CGM system and perform required calibrations using self-monitored blood glucose.~Exclusion Criteria:~* Male.~* Age \< 14 years.~* History of self-injurious behavior that the senior clinician feels precludes participation.~* Unable to understand the study protocol.~* Unwilling to follow the study protocol.~* Participation in any competing research study.~* Planned ISL admission for \<4 days.~* Pregnant.~* Not able to communicate in English.~* Regular use of acetaminophen or acetaminophen containing medications and not able to modify their medication to a non-acetaminophen based medication.

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ED-DMT1 and ED/only (Type: None): Eating Disorder and Type 1 Diabetes and only an Eating Disorder

Based on this trial design, predict the completion outcome and termination type (if applicable).